



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>C12N 15/10, C07K 14/47</b>	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/23464</b> <b>(43) International Publication Date:</b> 27 April 2000 (27.04.00)
<b>(21) International Application Number:</b> PCT/EP99/07742 <b>(22) International Filing Date:</b> 14 October 1999 (14.10.99)  <b>(30) Priority Data:</b> 09/173,941      16 October 1998 (16.10.98)      US  <b>(71) Applicant (for all designated States except AT US):</b> NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).  <b>(71) Applicant (for AT only):</b> NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).  <b>(71) Applicant (for all designated States except US):</b> THE SCRIPPS RESEARCH INSTITUTE [US/US]; 10550 North Torrey Pines Road, La Jolla, CA 92037 (US).  <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> BARBAS, Carlos, F. [US/US]; 755 Pacific Surf Drive, Solana Beach, CA 92075 (US).	<b>(74) Agent:</b> BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 16 November 2000 (16.11.00)	
<b>(54) Title:</b> ZINC FINGER BINDING DOMAINS FOR GNN  <b>(57) Abstract</b> <p>Zinc finger-nucleotide binding polypeptides having binding specificity for target nucleotides containing one or GNN triplets are provided. Compositions containing such polypeptides and the use of such polypeptides and compositions for regulating nucleotide function are also provided.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/07742

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/10 C07K14/47

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>T. OGAWA ET AL.,: "Enhanced expression in seminoma of human zinc finger genes located on chromosome 19"</p> <p>CANCER GENET. CYTOGENET.,</p> <p>vol. 100, no. 1,</p> <p>1 January 1998 (1998-01-01), pages 36-42,</p> <p>XP000882080</p> <p>* page 37, right column, last full-paragraph; figure 1A *</p> <p>---</p> <p>-/--</p>	<p>1-11,</p> <p>19-21</p>



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

27 March 2000

Date of mailing of the international search report

23.06.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Julia, P

## INTERNATIONAL SEARCH REPORT

Intern: 1st Application No

PCT/EP 99/07742

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	B. GEBELEIN ET AL.,: "A novel profile of expressed tags for zinc finger encoding genes from the poorly differentiated exocrine pancreatic cell line AR4IP" CANCER LETT., vol. 105, no. 2, 2 August 1996 (1996-08-02), pages 225-231, XP000882088 * whole document, in particular Table 1 *	1-11, 19-21
A	CHOO Y ET AL: "Selection of DNA binding sites for zinc fingers using rationally randomized DNA reveals coded interactions" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, 8 November 1994 (1994-11-08), pages 1168-1172, XP002075339 ISSN: 0027-8424 cited in the application * whole document, in particular figure 1 and page 11172, left-column, last paragraph to right-column, last paragraph *	1-21
A	CHOO Y ET AL: "Toward a code for the interactions of zinc fingers with DNA: Selection of randomized fingers displayed on phage" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA,US,NATIONAL ACADEMY OF SCIENCE. WASHINGTON, 8 November 1994 (1994-11-08), pages 1163-1167, XP002075340 ISSN: 0027-8424 cited in the application * whole document, in particular figure 2 *	1-21
Y	WO 96 06166 A (MEDICAL RES COUNCIL ;CHOO YEN (SG); KLUG AARON (GB); GARCIA ISIDRO) 29 February 1996 (1996-02-29) * whole document, in particular Table 1 and figures 4 and 7 *	1-21
Y	Q. LIU ET AL.,: "Design of polydactyl zinc-finger proteins for unique addressing within complex genomes" PROC. NATL. ACAD. SCI. USA, vol. 94, May 1997 (1997-05), pages 5525-5530, XP002918175 cited in the application * whole document, in particular page 5529, right-column *	1-21

# INTERNATIONAL SEARCH REPORT

Int. l. application No.  
PCT/EP 99/07742

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

See additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1 - 21 (partial)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

## 1. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 1; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 2-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 1; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 2. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 2; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1 or 3-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 2; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 3. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 3; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-2 or 4-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 3; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

compositions; medicament comprising these compositions and uses thereof

## 4. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 4; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-3 or 5-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 4; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 5. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 5; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-4 or 6-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 5; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 6. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 6; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-5 or 7-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 6; an isolated and purified

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 7. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 7; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-6 or 8-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 7; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 8. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 8; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-7 or 9-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 8; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 9. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 9; compositions comprising from 2 to about 12 of isolated and purified zinc



## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-8 or 10-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 9; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 10. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 10; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-9 or 11-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 10; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 11. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 11; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-10 or 12-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 11; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 12. Claims: 1-21 (partial)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 12; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-11 or 13-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 12; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 13. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 13; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-12 or 14-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 13; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 14. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 14; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-13 or 15-16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 14; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

compositions; medicament comprising these compositions and uses thereof

## 15. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 15; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-14 or 16 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 15; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

## 16. Claims: 1-21 (partial)

an isolated and purified zinc finger-nucleotide binding polypeptide that contains a nucleotide binding region having the sequence of SEQ ID No.: 16; compositions comprising from 2 to about 12 of isolated and purified zinc finger-nucleotide binding polypeptides containing the nucleotide binding regions having the sequence of any of SEQ ID No.: 1-15 and wherein at least one of said polypeptides contains the nucleotide binding region having the sequence of SEQ ID No.: 16; an isolated and purified polynucleotide encoding said polypeptide or compositions thereof; expression vectors; a process of regulating a nucleotide sequence that contains 5'-(GNN)n-3', where n is an integer from 1 to 6, the process comprising exposing the nucleotide sequence to an effective amount of these compositions; medicament comprising these compositions and uses thereof

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/JP 99/07742

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9606166 A	29-02-1996	AU 1003799 A	22-04-1999
		AU 698152 B	22-10-1998
		AU 3229195 A	14-03-1996
		CA 2196419 A	29-02-1996
		EP 0781331 A	02-07-1997
		JP 10504461 T	06-05-1998
		US 6013453 A	11-01-2000
		US 6007988 A	28-12-1999
-----			